期刊文献+
共找到1,726篇文章
< 1 2 87 >
每页显示 20 50 100
Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes:A new horizon 被引量:1
1
作者 Mahmoud Nassar Ajay Chaudhuri +1 位作者 Husam Ghanim Paresh Dandona 《World Journal of Diabetes》 SCIE 2024年第2期133-136,共4页
Type 1 diabetes(T1D)is a chronic autoimmune condition that destroys insulinproducing beta cells in the pancreas,leading to insulin deficiency and hyperglycemia.The management of T1D primarily focuses on exogenous insu... Type 1 diabetes(T1D)is a chronic autoimmune condition that destroys insulinproducing beta cells in the pancreas,leading to insulin deficiency and hyperglycemia.The management of T1D primarily focuses on exogenous insulin replacement to control blood glucose levels.However,this approach does not address the underlying autoimmune process or prevent the progressive loss of beta cells.Recent research has explored the potential of glucagon-like peptide-1 receptor agonists(GLP-1RAs)as a novel intervention to modify the disease course and delay the onset of T1D.GLP-1RAs are medications initially developed for treating type 2 diabetes.They exert their effects by enhancing glucose-dependent insulin secretion,suppressing glucagon secretion,and slowing gastric emptying.Emerging evidence suggests that GLP-1RAs may also benefit the treatment of newly diagnosed patients with T1D.This article aims to highlight the potential of GLP-1RAs as an intervention to delay the onset of T1D,possibly through their potential immunomodulatory and anti-inflammatory effects and preservation of beta-cells.This article aims to explore the potential of shifting the paradigm of T1D management from reactive insulin replacement to proactive disease modification,which should open new avenues for preventing and treating T1D,improving the quality of life and long-term outcomes for individuals at risk of T1D. 展开更多
关键词 Type 1 diabetes Semaglutide Glucagon-like peptide-1 receptor agonists Insulin therapy Autoimmune response Blood glucose monitoring Β-cell preservation Early screening Teplizumab Randomized controlled trials
下载PDF
Peroxisome proliferator-activated receptor agonists:A new hope towards the management of alcoholic liver disease
2
作者 Siva Sundara Kumar Durairajan Abhay Kumar Singh Ashok Iyaswamy 《World Journal of Gastroenterology》 SCIE CAS 2024年第35期3965-3971,共7页
In this editorial,we examine a paper by Koizumi et al,on the role of peroxisome proliferator-activated receptor(PPAR)agonists in alcoholic liver disease(ALD).The study determined whether elafibranor protected the inte... In this editorial,we examine a paper by Koizumi et al,on the role of peroxisome proliferator-activated receptor(PPAR)agonists in alcoholic liver disease(ALD).The study determined whether elafibranor protected the intestinal barrier and reduced liver fibrosis in a mouse model of ALD.The study also underlines the role of PPARs in intestinal barrier function and lipid homeostasis,which are both affected by ALD.Effective therapies are necessary for ALD because it is a critical health issue that affects people worldwide.This editorial analyzes the possibility of PPAR agonists as treatments for ALD.As key factors of inflammation and metabolism,PPARs offer multiple methods for managing the complex etiology of ALD.We assess the abilities of PPARα,PPARγ,and PPARβ/δagonists to prevent steatosis,inflammation,and fibrosis due to liver diseases.Recent research carried out in preclinical and clinical settings has shown that PPAR agonists can reduce the severity of liver disease.This editorial discusses the data analyzed and the obstacles,advantages,and mechanisms of action of PPAR agonists for ALD.Further research is needed to understand the efficacy,safety,and mechanisms of PPAR agonists for treating ALD. 展开更多
关键词 Alcoholic liver disease Peroxisome proliferator-activated receptors Peroxisome proliferator-activated receptors agonists Liver fibrosis INFLAMMATION Metabolic regulation HEPATOPROTECTION
下载PDF
The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity:A Meta-Analysis
3
作者 Mengqing Zhang Chu Lin +7 位作者 Xiaoling Cai Ruoyang Jiao Shuzhen Bai Zonglin Li Suiyuan Hu Fang Lyu Wenjia Yang Linong Ji 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2024年第6期607-616,共10页
Objective Recent studies have indicated potential anti-inflammatory effects of glucagon-like peptide-1 receptor agonists(GLP-1RAs)on asthma,which is often comorbid with type 2 diabetes mellitus(T2DM)and obesity.Theref... Objective Recent studies have indicated potential anti-inflammatory effects of glucagon-like peptide-1 receptor agonists(GLP-1RAs)on asthma,which is often comorbid with type 2 diabetes mellitus(T2DM)and obesity.Therefore,we conducted a meta-analysis to assess the association between the administration of glucagon-like peptide-1(GLP-1)receptor-based agonists and the incidence of asthma in patients with T2DM and/or obesity.Methods PubMed,Web of Science,Embase,the Cochrane Central Register of Controlled Trials,and Clinicaltrial.gov were systematically searched from inception to July 2023.Randomized controlled trials(RCTs)of GLP-1 receptor-based agonists(GLP-1RA,GLP-1 based dual and triple receptor agonist)with reports of asthma events were included.Outcomes were computed as risk ratios(RR)using a fixedeffects model.Results Overall,39 RCTs with a total of 85,755 participants were included.Compared to non-GLP-1 receptor-based agonist users,a trend of reduced risk of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments,although the difference was not statistically significant[RR=0.91,95%confidence interval(CI):0.68 to 1.24].Further Subgroup analyses indicated that the use of light-molecular-weight GLP-1RAs might be associated with a reduced the risk of asthma when compared with non-users(RR=0.65,95%CI:0.43 to 0.99,P=0.043).We also performed sensitivity analyses for participant characteristics,study design,drug structure,duration of action,and drug subtypes.However,no significant associations were observed.Conclusion Compared with non-users,a modest reduction in the incidence of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments.Further investigations are warranted to assess the association between GLP-1 receptor-based agonists and the risk of asthma. 展开更多
关键词 Glucagon-like peptide-1 receptor agonists Twincretins ASTHMA Type 2 diabetes mellitus OBESITY
下载PDF
GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
4
作者 Jiani Zhong Hang Chen +3 位作者 Qiming Liu Shenghua Zhou Zhenguo Liu Yichao Xiao 《Journal of Pharmaceutical Analysis》 SCIE CAS CSCD 2024年第5期653-665,共13页
Atrial fibrillation(AF)is the most common cardiac arrhythmia.Many medical conditions,including hypertension,diabetes,obesity,sleep apnea,and heart failure(HF),increase the risk for AF.Cardiomyocytes have unique metabo... Atrial fibrillation(AF)is the most common cardiac arrhythmia.Many medical conditions,including hypertension,diabetes,obesity,sleep apnea,and heart failure(HF),increase the risk for AF.Cardiomyocytes have unique metabolic characteristics to maintain adenosine triphosphate production.Significant changes occur in myocardial metabolism in AF.Glucagon-like peptide-1 receptor agonists(GLP-1RAs)have been used to control blood glucose fluctuations and weight in the treatment of type 2 diabetes mellitus(T2DM)and obesity.GLP-1RAs have also been shown to reduce oxidative stress,inflammation,autonomic nervous system modulation,and mitochondrial function.This article reviews the changes in metabolic characteristics in cardiomyocytes in AF.Although the clinical trial outcomes are unsatisfactory,the findings demonstrate that GLP-1 RAs can improve myocardial metabolism in the presence of various risk factors,lowering the incidence of AF. 展开更多
关键词 Atrial fibrillation Glucagon-like peptide-1 receptor agonists METABOLISM
下载PDF
Practical guide:Glucagon-like peptide-1 and dual glucosedependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus
5
作者 Saleh Fahad Alqifari Omar Alkomi +13 位作者 Abdullah Esmail Khadijeh Alkhawami Shahd Yousri Mohamad Ayham Muqresh Nawwarah Alharbi Abdullah A Khojah Ahmed Aljabri Abdulrahman Allahham Kousalya Prabahar Hanan Alshareef Mohammed Aldhaeefi Tariq Alrasheed Ali Alrabiah Laila A AlBishi 《World Journal of Diabetes》 SCIE 2024年第3期331-347,共17页
Practical guide:Glucagon-like peptide-1 and dual glucosedependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus common second-line choice after metformin for treating T2... Practical guide:Glucagon-like peptide-1 and dual glucosedependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus common second-line choice after metformin for treating T2DM.Various considerations can make selecting and switching between different GLP-1 RAs challenging.Our study aims to provide a comprehensive guide for the usage of GLP-1 RAs and dual GIP and GLP-1 RAs for the management of T2DM. 展开更多
关键词 Glucagon-like peptide-1 receptor agonist Diabetes mellitus Metabolic syndrome Dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist Clinical practice ENDOCRINOLOGY
下载PDF
Interplay of gut microbiota,glucagon-like peptide receptor agonists,and nutrition:New frontiers in metabolic dysfunction-associated steatotic liver disease therapy
6
作者 Merve Guney-Coskun Metin Basaranoglu 《World Journal of Gastroenterology》 SCIE CAS 2024年第43期4682-4688,共7页
The gut-liver axis plays a crucial role in the development and progression of metabolic dysfunction-associated steatotic liver disease(MASLD).Key metabolites,including lipopolysaccharides,short-chain fatty acids(SCFAs... The gut-liver axis plays a crucial role in the development and progression of metabolic dysfunction-associated steatotic liver disease(MASLD).Key metabolites,including lipopolysaccharides,short-chain fatty acids(SCFAs),bile acids,and beneficial gut bacteria such as Bifidobacterium and Lactobacillus,are pivotal in this process.Glucagon-like peptide-1 receptor agonists(GLP-1 RAs)show promise in managing MASLD by promoting weight loss,enhancing insulin secretion,and improving liver health.They restore gut-liver axis functionality,and their effects are amplified through dietary modifications and gut microbiometargeted therapies.Emerging research highlights the interplay between GLP-1 RAs and gut microbiota,indicating that the gut microbiome significantly influences therapeutic outcomes.Metabolites produced by gut bacteria,can stimulate glucagon-like peptide-1(GLP-1)secretion,further improving metabolic health.Integrating dietary interventions with GLP-1 RA treatment may enhance liver health by modulating the gut microbiota-SCFAs-GLP-1 pathway.Future research is needed to understand personalized effects,with prebiotics and probiotics offering treatment avenues for MASLD. 展开更多
关键词 Metabolic dysfunction-associated steatotic liver disease Glucagon-like peptide-1 receptor agonists Gut microbiome Gut-liver axis Diet intervention
下载PDF
Glucagon-like peptide-1 agonists:Role of the gut in hypoglycemia unawareness,and the rationale in type 1 diabetes
7
作者 Hyder O Mirghani 《World Journal of Diabetes》 SCIE 2024年第11期2167-2172,共6页
Type 1 diabetes is increasing and the majority of patients have poor glycemic control.Although advanced technology and nanoparticle use have greatly enhanced insulin delivery and glucose monitoring,weight gain and hyp... Type 1 diabetes is increasing and the majority of patients have poor glycemic control.Although advanced technology and nanoparticle use have greatly enhanced insulin delivery and glucose monitoring,weight gain and hypoglycemia remain major challenges and a constant source of concern for patients with type 1 diabetes.Type 1 diabetes shares some pathophysiology with type 2 diabetes,and an overlap has been reported.The above observation created great interest in glucagon-like peptide-1 receptor agonists(GLP-1)as adjuvants for type 1 diabetes.Previous trials confirmed the positive influence of GLP-1 agonists onβcell function.However,hypoglycemia unawareness and dysregulated glucagon response have been previously reported in patients with recurrent hypoglycemia using GLP-1 agonists.Jin et al found that the source of glucagon dysregulation due to GLP-1 agonists resides in the gut.Plausible explanations could be gut nervous system dysregulation or gut microbiota disruption.This review evaluates the potential of GLP-1 agonists in managing type 1 diabetes,particularly focusing on their impact on glycemic control,weight management,and glucagon dysregulation.We provide a broader insight into the problem of type 1 diabetes mellitus management in the light of recent findings and provide future research directions. 展开更多
关键词 Glucagon-like peptide-1 receptor agonists Glucagon response Hypoglycemia unawareness GUT Type 1 diabetes
下载PDF
Impact of glucagon-like peptide receptor agonists on endoscopy and its preoperative management: Guidelines, challenges, and future directions
8
作者 Sahib Singh Vishnu Charan Suresh Kumar Ganesh Aswath 《World Journal of Gastrointestinal Endoscopy》 2024年第6期292-296,共5页
Glucagon-like peptide receptor agonists(GLP-1RA)are used to treat type 2 diabetes mellitus and,more recently,have garnered attention for their effect-iveness in promoting weight loss.They have been associated with sev... Glucagon-like peptide receptor agonists(GLP-1RA)are used to treat type 2 diabetes mellitus and,more recently,have garnered attention for their effect-iveness in promoting weight loss.They have been associated with several gastrointestinal adverse effects,including nausea and vomiting.These side effects are presumed to be due to increased residual gastric contents.Given the potential risk of aspiration and based on limited data,the American Society of Anesthesi-ologists updated the guidelines concerning the preoperative management of patients on GLP-1RA in 2023.They included the duration of mandated cessation of GLP-1RA before sedation and usage of“full stomach”precautions if these medications were not appropriately held before the procedure.This has led to additional challenges,such as extended waiting time,higher costs,and increased risk for patients.In this editorial,we review the current societal guidelines,clinical practice,and future directions regarding the usage of GLP-1RA in patients undergoing an endoscopic procedure. 展开更多
关键词 Glucagon-like peptide receptor agonists ENDOSCOPY Adverse events INTUBATION ASPIRATION Semaglutide Healthcare burden GUIDELINES
下载PDF
Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease:Opportunities and challenges
9
作者 Chencheng Xie Naim Alkhouri Mohamed A Elfeki 《World Journal of Hepatology》 2024年第5期731-750,共20页
Metabolic dysfunction-associated steatotic liver disease(MASLD)has become the most common chronic liver disease worldwide,paralleling the rising pandemic of obesity and type 2 diabetes.Due to the growing global health... Metabolic dysfunction-associated steatotic liver disease(MASLD)has become the most common chronic liver disease worldwide,paralleling the rising pandemic of obesity and type 2 diabetes.Due to the growing global health burden and com-plex pathogenesis of MASLD,a multifaceted and innovative therapeutic approach is needed.Incretin receptor agonists,which were initially developed for diabetes management,have emerged as promising candidates for MASLD treatment.This review describes the pathophysiological mechanisms and action sites of three major classes of incretin/glucagon receptor agonists:glucagon-like peptide-1 receptor agonists,glucose-dependent insulinotropic polypeptide receptor agonists,and glucagon receptor agonists.Incretins and glucagon directly or indirectly impact various organs,including the liver,brain,pancreas,gastro-intestinal tract,and adipose tissue.Thus,these agents significantly improve glycemic control and weight management and mitigate MASLD pathogenesis.Importantly,this study provides a summary of clinical trials analyzing the effect-iveness and safety of incretin receptor agonists in MASLD management and provides an in-depth analysis highlighting their beneficial effects on improving liver function,hepatic steatosis,and intrahepatic inflammation.There are emerging challenges associated with the use of these medications in the real world,particularly adverse events,drug-drug interactions,and barriers to access,which are discussed in detail.Additionally,this review highlights the evolving role of incretin receptor agonists in MASLD management and suggests future research directions. 展开更多
关键词 Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatohepatitis Glucagon-like peptide-1 Glucose-dependent inulinotropic polypeptide GLUCAGON INCRETIN Receptor agonist
下载PDF
Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes:A systematic review with multiple network meta-regressions
10
作者 Jing-Jing Zhu John P H Wilding Xiao-Song Gu 《World Journal of Diabetes》 SCIE 2024年第10期2135-2146,共12页
BACKGROUND Glucagon-like peptide-1 receptor agonists(GLP-1RA)and sodium-glucose co-transporter-2 inhibitors(SGLT-2I)are associated with significant cardiovascular benefit in type 2 diabetes(T2D).However,GLP-1RA or SGL... BACKGROUND Glucagon-like peptide-1 receptor agonists(GLP-1RA)and sodium-glucose co-transporter-2 inhibitors(SGLT-2I)are associated with significant cardiovascular benefit in type 2 diabetes(T2D).However,GLP-1RA or SGLT-2I alone may not improve some cardiovascular outcomes in patients with prior cardiovascular co-morbidities.AIM To explore whether combining GLP-1RA and SGLT-2I can achieve additional benefit in preventing cardiovascular diseases in T2D.METHODS The systematic review was conducted according to PRISMA recommendations.The protocol was registered on PROSPERO(ID:42022385007).A total of 107049 participants from eligible cardiovascular outcomes trials of GLP-1RA and SGLT-2I were included in network meta-regressions to estimate cardiovascular benefit of the combination treatment.Effect modification of prior myocardial infarction(MI)and heart failure(HF)was also explored to provide clinical insight as to when the INTRODUCTION The macro-and micro-vascular benefits of glucagon-like peptide-1 receptor agonists(GLP-1RA)and sodium-glucose co-transporter-2 inhibitors(SGLT-2I)are independent of their glucose-lowering effects[1].In patients with type 2 diabetes(T2D),the major cardiovascular outcome trials(CVOT)showed that dipeptidyl peptidase-4 inhibitors(DPP-4I)did not improve cardiovascular outcomes[2],whereas cardiovascular benefit of GLP-1RA or SGLT-2I was significant[3,4].Further subgroup analyses indicated that the background cardiovascular risk should be considered when examining the cardiovascular outcomes of these newer glucose-lowering medications.For instance,prevention of major adverse cardiovascular events(MACE)was only seen in those patients with baseline atherosclerotic cardiovascular disease[3,4].Moreover,a series of CVOT conducted in patients with heart failure(HF)have demonstrated that(compared with placebo)SGLT-2I significantly reduced risk of hospitalization for HF or cardiovascular death,irrespective of their history of T2D[5-8].However,similar cardiovascular benefits were not observed in those with myocardial infarction(MI)[9,10].Cardiovascular co-morbidities are not only approximately twice as common but are also associated with dispropor-tionately worse cardiovascular outcomes in patients with T2D,compared to the general population[11].Therefore,it is of clinical importance to investigate whether the combination treatment of GLP-1RA and SGLT-2I could achieve greater cardiovascular benefit,particularly when considering patients with cardiovascular co-morbidities who may not gain sufficient cardiovascular protection from the monotherapies.This systematic review with multiple network meta-regressions was mainly aimed to explore whether combining GLP-1RA and SGLT-2I can provide additional cardiovascular benefit in T2D.Cardiovascular outcomes of these newer antidiabetic medications were also estimated under effect modification of prior cardiovascular diseases.This was to provide clinical insight as to when the combination treatment might be prioritized. 展开更多
关键词 Type 2 diabetes Glucagon-like peptide-1 receptor agonist Sodium-glucose co-transporter-2 inhibitor Combination treatment Cardiovascular outcome Systematic review Network meta-regression
下载PDF
Glucagon-like peptide-1 receptor agonists:Exploring the mechanisms from glycemic control to treatment of multisystemic diseases
11
作者 Mo-Wei Kong Yang Yu +2 位作者 Ying Wan Yu Gao Chun-Xiang Zhang 《World Journal of Gastroenterology》 SCIE CAS 2024年第36期4036-4043,共8页
This editorial takes a deeper look at the insights provided by Soresi and Giannitrapani,which examined the therapeutic potential of glucagon-like peptide-1 receptor agonists(GLP-1RAs)for metabolic dysfunction-associat... This editorial takes a deeper look at the insights provided by Soresi and Giannitrapani,which examined the therapeutic potential of glucagon-like peptide-1 receptor agonists(GLP-1RAs)for metabolic dysfunction-associated fatty liver disease.We provide supplementary insights to their research,highlighting the broader systemic implications of GLP-1RAs,synthesizing the current understanding of their mechanisms and the trajectory of research in this field.GLP-1RAs are revolutionizing the treatment of type 2 diabetes mellitus and beyond.Beyond glycemic control,GLP-1RAs demonstrate cardiovascular and renal protective effects,offering potential in managing diabetic kidney disease alongside renin–angiotensin–aldosterone system inhibitors.Their role in bone metabolism hints at benefits for diabetic osteoporosis,while the neuroprotective properties of GLP-1RAs show promise in Alzheimer's disease treatment by modulating neuronal insulin signaling.Additionally,they improve hormonal and metabolic profiles in polycystic ovary syndrome.This editorial highlights the multifaceted mechanisms of GLP-1RAs,emphasizing the need for ongoing research to fully realize their therapeutic potential across a range of multisystemic diseases. 展开更多
关键词 Glucagon-like peptide-1 receptor agonists Glycemic control Multisystem diseases Mechanism of action Cardiovascular protection Renal disease Bone metabolism Non-alcoholic fatty liver disease NEUROPROTECTION Polycystic ovary syndrome
下载PDF
A Retrospective Analysis of Glucagon-Like Peptide 1 Receptor Agonists in Treating Type 2 Diabetes Mellitus Complicated by Nonalcoholic Fatty Liver Disease
12
作者 Jiaqian Chen Hongyan Wu 《Journal of Biosciences and Medicines》 2024年第3期16-24,共9页
Background: The objective of this study was to compare and analyze the variations in clinical indices before and after treatment of type 2 mellitus (T2DM) combined with nonalcoholic fatty liver disease (NAFLD) that we... Background: The objective of this study was to compare and analyze the variations in clinical indices before and after treatment of type 2 mellitus (T2DM) combined with nonalcoholic fatty liver disease (NAFLD) that were treated with glucagon-like peptide 1 receptor agonists (GLP-1RAs). Methods: The electronic medical record system was utilized to search for a total of 16 patients with type 2 diabetes complicated by NAFLD who were hospitalized at the First Affiliated Hospital of Yangtze University from October 2022 to April 2023 and treated with GLP-1RA for the first time. The clinical indices were compared before and after 12 weeks of treatment with GLP-1RA. Results: The liver-spleen CT ratio (L/S), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) in all patients treated with GLP-1RA after 12 weeks were significantly different (P 0.05). The patients were categorized into two groups based on the types of GLP-1RAs. The changes in L/S, TC, TG, and LDL-C in the long-acting group after treatment were statistically significant (P Conclusions: GLP-1RAs can improve liver function, regulate lipid metabolism, and reduce the severity of fatty liver in patients with T2DM complicated by NAFLD, which demonstrates the importance of clinical applications. 展开更多
关键词 Glucagon-Like Peptide 1 Receptor agonists Nonalcoholic Fatty Liver Disease Type 2 Diabetes Mellitus
下载PDF
半夏泻心汤调控TLRs/NF-κB/MyD88信号通路干预溃疡性结肠炎的实验研究 被引量:3
13
作者 李室箕 张林 +5 位作者 牟永旭 朱烔依 罗文晔 王杰 谢田炜 陈兰秋 《世界科学技术-中医药现代化》 CSCD 北大核心 2023年第3期1133-1139,共7页
目的观察半夏泻心汤对溃疡性结肠炎(Ulcerative colitis,UC)大鼠肠道粘膜中的Toll样受体(Toll-like receptors,TLRs)/核转录因子κB(Nuclear factor kappa-light-chain-enhancer of activated B cells,NF-κB)/髓样分化蛋白88(Myeloid d... 目的观察半夏泻心汤对溃疡性结肠炎(Ulcerative colitis,UC)大鼠肠道粘膜中的Toll样受体(Toll-like receptors,TLRs)/核转录因子κB(Nuclear factor kappa-light-chain-enhancer of activated B cells,NF-κB)/髓样分化蛋白88(Myeloid differentiation factor SS,MyD88)信号通路及抑制因子基质金属蛋白酶(Matrix metalloproteinases,MMPs)MMP-1、MMP-2表达影响,并探讨其作用机制。方法建立葡聚糖硫酸钠盐(Dextran sulphate sodium salt,DSS)诱导产生UC模型,根据随机数字表法,将35只无特定病原体(Specific pathogen free,SPF)级大鼠进行分组,分为正常组、模型组、低浓度给药组(0.473 g·mL^(-1))、中浓度给药组(0.945 g·mL^(-1))和高浓度给药组(1.890 g·mL^(-1))。除正常组外,其余4组大鼠连续10天使用2.5%浓度的葡聚糖硫酸钠盐溶液每天2 mL进行灌胃,造模成功后,连续给药1周,观察大鼠疾病活动指数(Disease activity index,DAI)变化;采用苏木精-伊红(Hematoxylin-eosin,HE)染色法,确认结肠组织病变损伤程度;同时应用蛋白质免疫印迹试验(Western blot)法,检测TLR4、NF-κB、MyD88蛋白在各组大鼠结肠中的表达;实时荧光定量聚合酶链反应(Real-time fluorescent quantitative polymerase chain reaction,RT-PCR)技术则测定了大鼠结肠黏膜TLR4、NF-κB、IκB-α(人核因子κB抑制蛋白α,NF-κB inhibitorα)、MMP-1、MMP-2的mRNA的表达。结果造模后大鼠体质量、食欲、被毛、活动度、尿量较造模前均出现不同程度的下降,同时部分大鼠出现腹泻、便血的症状。模型组与正常组相比,大鼠结肠组织中TLR4、NF-κB、MyD88蛋白的表达,及TLR4、NF-κB、IκB-α、MMP-1、MMP-2的mRNA表达均显著升高(P<0.01);给予半夏泻心汤治疗后,UC大鼠体质量下降、腹泻、便血等症状明显减轻。低、中、高剂量的半夏泻心汤实验组中,大鼠结肠黏膜组织TLR4、NF-κB、MyD88蛋白的表达相较于模型组有不同程度地降低;MMP-1、MMP-2水平也有所下降。结论半夏泻心汤可能通过影响TLRs/NF-κB/MyD88信号通路及其相关因子的表达,改善溃疡性结肠炎大鼠结肠损伤程度,进而防治UC。 展开更多
关键词 半夏泻心汤 溃疡性结肠炎 tlrs/NF-κB/MyD88信号通路 TOLL样受体 基质金属蛋白酶
下载PDF
The seeming paradox of adenosine receptors as targets for the treatment of Alzheimer's disease: agonists or antagonists? 被引量:1
14
作者 Rubina Marzagalli Alessandro Castorina 《Neural Regeneration Research》 SCIE CAS CSCD 2015年第2期205-207,共3页
Alzheimer's disease (AD) is the most common neurodegenerative disorder, and its incidence is relatively high among elderly people, affecting about 1-2% of the population between 60-65 years old and rising dramatica... Alzheimer's disease (AD) is the most common neurodegenerative disorder, and its incidence is relatively high among elderly people, affecting about 1-2% of the population between 60-65 years old and rising dramatically (about 30%) in people aged 80 years or older (Selkoe, 2002). Nowadays, considering the increasing mean lifespan of populations in developed countries, the disease is becoming more and more a health concern, and the search for an effective cure has turned into"a real need". 展开更多
关键词 The seeming paradox of adenosine receptors as targets for the treatment of Alzheimer’s disease agonists or antagonists
下载PDF
Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients
15
作者 Xiao-Min Huang Xing Zhong +2 位作者 Yi-Jun Du Yan-Yun Guo Tian-Rong Pan 《World Journal of Diabetes》 SCIE 2023年第8期1280-1288,共9页
BACKGROUND Currently,the lack of comparative studies between weekly and daily formulations of glucagon-like peptide-1 receptor agonists(GLP-1RAs)for glucose excursion is worth investigation.AIM To investigate the effe... BACKGROUND Currently,the lack of comparative studies between weekly and daily formulations of glucagon-like peptide-1 receptor agonists(GLP-1RAs)for glucose excursion is worth investigation.AIM To investigate the effects of weekly and daily formulations of GLP-1RA on glucose excursion and inflammation in overweight and obese patients with type 2 diabetes.METHODS Seventy patients with type 2 diabetes mellitus who were treated at our hospital between January 2019 and January 2022 were enrolled in this retrospective analysis.All patients were treated with metformin.We evaluated changes in blood glucose levels and a series of important indicators in patients before and after treatment with either a weekly or daily preparation of GLP-1RA(group A;n=33 and group B;n=37).RESULTS The degree of decrease in the levels of fasting blood glucose,mean blood glucose,mean amplitude of glycemic excursions,total cholesterol,triglycerides,tumor necrosis factor-α,interleukin-6,and high-sensitivity C-reactive protein after treatment in group A was higher than that in group B(P<0.05),whereas the 2-h postprandial blood glucose levels decreased more so in group B than in group A(P<0.001).However,there were no statistically significant differences in the levels of glycated hemoglobin,standard deviation of blood glucose,coefficient of variation,absolute mean of daily differences,percentage of time with 3.9 mmol/L<glucose<10 mmol/L,and high-and low-density lipoproteins between the two groups(P>0.05).The incidence of adverse reactions was significantly lower in group A than in group B(P<0.05).CONCLUSION The effect of the weekly preparation of GLP-1RA in controlling blood glucose levels in the patients,suppressing inflammation,and reducing adverse reactions was significantly higher than that of the daily preparations,which is worthy of clinical promotion. 展开更多
关键词 Glucagon-like peptide-1 receptor agonists Weekly preparation Daily preparation Overweight or obese Type 2 diabetes mellitus Glucose excursion INFLAMMATION
下载PDF
血小板生成素受体激动剂治疗化疗相关性血小板减少症的研究现状 被引量:2
16
作者 陈露 陈玥睎 +4 位作者 张玉洁 赵晓丽 周寒丽 段方方 孔天东 《现代肿瘤医学》 CAS 2024年第10期1912-1917,共6页
化疗相关性血小板减少症(chemotherapy-induced thrombocytopenia, CIT)仍是目前肿瘤治疗的严重并发症,既往针对CIT的处理主要为输注血小板、使用重组人白介素-11(recombinanthumaninterleukin-11,rhIL-11)及重组人血小板生成素(recombi... 化疗相关性血小板减少症(chemotherapy-induced thrombocytopenia, CIT)仍是目前肿瘤治疗的严重并发症,既往针对CIT的处理主要为输注血小板、使用重组人白介素-11(recombinanthumaninterleukin-11,rhIL-11)及重组人血小板生成素(recombinanthuman thrombopoietin, rhTPO)等,但对一些难治性CIT,效果有限。近年来,新型血小板生成素受体激动剂(thrombopoietin receptor agonists, TPO-RAs)已上市并用于血小板减少症,但尚未批准用于CIT治疗。本文对TPO-RAs类药物在CIT方面已开展的临床研究进行汇总,结果显示罗米司亭、艾曲泊帕、阿伐曲泊帕研究相对较多,但多为小样本或单中心回顾性分析,而芦曲泊帕和海曲泊帕尚缺乏治疗CIT的临床研究。 展开更多
关键词 血小板生成素受体激动剂 化疗相关性血小板减少症 罗米司亭 艾曲泊帕 阿伐曲泊帕 海曲泊帕 芦曲泊帕
下载PDF
苦味受体的非味觉功能研究进展 被引量:2
17
作者 王辉 冯平 《广西师范大学学报(自然科学版)》 CAS 北大核心 2024年第1期18-27,共10页
苦味的识别对动物生存至关重要,该过程由苦味受体介导。食物中的化学物质刺激口腔内的苦味感受器,经信号传导反馈给大脑,产生苦味感知并最终影响食物的选择和排斥。除了基本的味觉功能,苦味受体在口腔外的其他器官和组织中普遍表达,在... 苦味的识别对动物生存至关重要,该过程由苦味受体介导。食物中的化学物质刺激口腔内的苦味感受器,经信号传导反馈给大脑,产生苦味感知并最终影响食物的选择和排斥。除了基本的味觉功能,苦味受体在口腔外的其他器官和组织中普遍表达,在细胞增殖、代谢调控、免疫反应等重要的生理生化过程中发挥作用。尽管苦味受体的蛋白结构仍未得到全部解析,具体的功能和作用机制未知,但由于其亚型众多且分布广泛,是理想的靶点,并将成为各类疾病治疗的重要探究方向。本文介绍苦味受体在口腔外部分器官组织中的表达和在相关疾病中的研究进展,有助于全面系统理解苦味受体的重要作用。 展开更多
关键词 苦味受体 味觉功能 苦味激动剂 代谢调控
下载PDF
司美格鲁肽对2型糖尿病合并超重及肥胖患者的胰腺和肝脏脂肪含量以及胰岛β细胞功能的影响 被引量:1
18
作者 黄华英 华建军 楼雪勇 《浙江医学》 CAS 2024年第12期1286-1290,共5页
目的探讨司美格鲁肽对2型糖尿病(T2DM)合并超重及肥胖患者的血糖控制、胰腺和肝脏脂肪含量以及胰岛β细胞功能的影响。方法采用单中心、前瞻性、临床病例对照试验的方法,选取2021年10月至2022年10月在金华市中心医院诊断为T2DM合并超重(... 目的探讨司美格鲁肽对2型糖尿病(T2DM)合并超重及肥胖患者的血糖控制、胰腺和肝脏脂肪含量以及胰岛β细胞功能的影响。方法采用单中心、前瞻性、临床病例对照试验的方法,选取2021年10月至2022年10月在金华市中心医院诊断为T2DM合并超重(BMI 25~<28 kg/m^(2))及肥胖(BMI≥28 kg/m^(2))的86例患者为研究对象,均接受稳定剂量的二甲双胍单药或联合口服用药至少3个月,糖化血红蛋白(HbA1C)为6.5%~8.0%。采用随机数字表法将患者分为对照组和观察组,各43例。对照组继续原方案口服降糖,观察组在原方案的基础上联合司美格鲁肽(起始剂量0.25 mg,4周后增加至0.5 mg并稳定,1次/周,皮下注射)。两组均干预24周。比较两组患者血糖(FPG、餐后2 h血糖和HbA1C)、血脂(TC、TG、LDL-C、HDL-C)、BMI、腰围、胰岛细胞功能[空腹胰岛素(FINS)、胰岛β细胞功能指数(HOMA-β)和胰岛素抵抗指数(HOMA-IR)]。通过非对称回波的最小二乘估算法迭代水脂分离序列测量胰头、胰体和胰尾的胰腺脂肪分数(PFF),计算平均PFF并进行组间比较;测量肝脏右上、右下和左叶的肝脏脂肪分数(HFF),计算平均HFF并进行组间比较。结果对照组39例和观察组40例随访至研究结束。治疗后观察组患者FPG、餐后2 h血糖、HbA1C、BMI、FINS、HOMA-IR、平均PFF和平均HFF均低于对照组,而HOMA-β高于对照组,差异均有统计学意义(均P<0.01)。结论司美格鲁肽应用方便,对T2DM合并超重及肥胖患者能够在常规降糖药的基础上进一步改善胰岛素和胰岛β细胞功能,降低血糖水平、胰腺和肝脏脂肪含量,同时可产生额外的减重获益。 展开更多
关键词 胰高血糖素样肽1受体激动剂 司美格鲁肽 2型糖尿病 超重 肥胖 磁共振 脂肪分数
下载PDF
青少年体内35种抗生素和4种β-受体激动剂的测定及暴露现状分析
19
作者 胡小键 李振环 +2 位作者 谢琳娜 付慧 朱英 《色谱》 CAS CSCD 北大核心 2024年第2期185-193,共9页
为了解我国青少年体内抗生素和β-受体激动剂的暴露水平,本研究采用同位素稀释-高通量全自动固相萃取-超高效液相色谱-串联质谱法测定某中学442名青少年(11~15岁)尿液中的7类共35种抗生素(5种大环内酯类、4种四环素类、10种喹诺酮类、3... 为了解我国青少年体内抗生素和β-受体激动剂的暴露水平,本研究采用同位素稀释-高通量全自动固相萃取-超高效液相色谱-串联质谱法测定某中学442名青少年(11~15岁)尿液中的7类共35种抗生素(5种大环内酯类、4种四环素类、10种喹诺酮类、3种β-内酰胺类、11种磺胺类、1种喹噁啉类和1种林可酰胺类)和4种β-受体激动剂的水平。尿样测定结果采用尿肌酐进行校正,所得到的样品检出率用于统计分析。采用皮尔森卡方检验对目标物检出率与性别、年龄和体重等级间的相关性进行分析。在调整了混杂因素后,采用Logistic回归模型来评估目标物检出率与不同组别间的相关性。分析结果发现,442名青少年中有397名青少年的尿液中检出抗生素或β-受体激动剂,总体检出率为89.8%。除喹噁啉类抗生素未被检出外,实验中共有6类27种抗生素和2种β-受体激动剂被检出,检出率为0.2%~59.0%;其中强力霉素、土霉素和阿奇霉素的检出率最高,检出率分别为59.0%、56.1%和34.6%;四环素类和大环内酯类抗生素是主要检出的两类抗生素,检出率分别为81.9%和42.3%;优先作为兽用的抗生素检出率最高(85.1%),其次为人用抗生素(41.0%),β-受体激动剂的总体检出率为2.7%。统计分析发现,四环素类抗生素在男性青少年尿液中的检出率高于女性,男性检出风险是女性的2.17倍。大环内酯类抗生素在不同年龄组间的检出率存在差异,与11岁青少年组相比,12、13岁青少年组的检出风险更高。实验发现,大环内酯类抗生素的检出率与青少年的肥胖程度呈正相关;在调整了年龄和性别因素后,肥胖青少年尿液中大环内酯类抗生素的检出风险是正常体重者的2.35倍。研究结果表明,青少年普遍暴露于低剂量的抗生素,且食物和环境中的抗生素可能是青少年体内抗生素暴露的主要来源,大环内酯类抗生素的暴露可能与青少年的肥胖风险相关。 展开更多
关键词 超高效液相色谱-串联质谱 抗生素 β-受体激动剂 青少年 尿液 暴露分析
下载PDF
达格列净联合胰高血糖素样肽-1受体激动剂对2型糖尿病的疗效研究
20
作者 洪冠宇 纪春敏 刘加河 《实用临床医药杂志》 CAS 2024年第7期90-95,共6页
目的探讨达格列净联合胰高血糖素样肽-1受体激动剂(GLP-1 RAs)对2型糖尿病患者血液流变学及胰岛素抵抗的影响。方法将2020年11月—2022年10月泉州市中医院收治的102例2型糖尿病患者随机分为2组,每组51例。对照组给予达格列净治疗,研究... 目的探讨达格列净联合胰高血糖素样肽-1受体激动剂(GLP-1 RAs)对2型糖尿病患者血液流变学及胰岛素抵抗的影响。方法将2020年11月—2022年10月泉州市中医院收治的102例2型糖尿病患者随机分为2组,每组51例。对照组给予达格列净治疗,研究组采用达格列净联合GLP-1 RAs(利拉鲁肽)的治疗方案。比较2组临床疗效、血糖指标[空腹血糖(FBG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)]、空腹胰岛素(FINS)及胰岛素抵抗[胰岛素抵抗指数(HOMA-IR)、胰岛素分泌指数(HOMA-β)]、血脂指标[总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]、血液流变学指标[红细胞聚集指数(EAI)、红细胞压积(HCT)、红细胞变形指数(EDI)、血浆黏度(PV)]和不良反应。结果研究组总有效率为94.12%,高于对照组的80.39%,差异有统计学意义(P<0.05)。研究组和对照组治疗后FBG、2 hPG、HbAlc、BMI均低于治疗前,且研究组治疗后FBG、2 hPG、HbAlc水平低于对照组,差异有统计学意义(P<0.05)。治疗后,研究组FINS、HOMA-β水平高于对照组,HOMA-IR水平低于对照组,差异有统计学意义(P<0.05)。研究组和对照组治疗后HDL-C均高于治疗前,TC、TG、LDL-C水平均低于治疗前;研究组治疗后HDL-C水平高于对照组,TC、TG、LDL-C水平低于对照组,差异均有统计学意义(P<0.05)。治疗后,研究组和对照组EAI、HCT、EDI、PV水平均低于治疗前,且研究组EAI、HCT、EDI、PV水平低于对照组,差异均有统计学意义(P<0.05)。研究组不良反应总发生率为11.76%,与对照组的9.80%比较,差异无统计学意义(P>0.05)。结论达格列净联合GLP-1 RAs(利拉鲁肽)治疗2型糖尿病的疗效确切,可有效调节患者血糖及血脂水平,缓解胰岛素抵抗,改善血液流变学指标。 展开更多
关键词 2型糖尿病 达格列净 胰高血糖素样肽-1受体激动剂 血液流变学 胰岛素抵抗
下载PDF
上一页 1 2 87 下一页 到第
使用帮助 返回顶部